Cancer diagnosis for solid tumors has traditionally relied on biopsied tumor tissue. For patients already diagnosed with lung cancer, blood-based liquid biopsies are increasingly being used to look for bits of tumor proteins or DNA that can help identify suitable treatment options. The US FDA has even approved two liquid biopsies that can detect actionable mutations in lung cancer. However, there are several liquid biopsies technologies, and researchers are exploring whether those could be used to answer other questions in the cancer space, such as: Early detection: Is cancer present? If so,… Read More

Well, we finally moved on to 2021, only to be thrust seemingly backward to #WCLC20!  The incredible content from #WCLC20 was certainly worth the wait.  Although we didn’t get to experience the meeting live together in Singapore, a new virtual platform brought it all to us in the comfort of our own homes. Several topics discussed at #WCLC20 stood out and deserve a deeper dive within the #LCSM community. There was a great deal of buzz about the TALENT study from Taiwan which looked at lung cancer screening in never or light… Read More